Rituximab News and Research

RSS
Rituximab is approved by the Food and Drug Administration (FDA) to be used alone or with other drugs to treat certain types of B-cell non-Hodgkin lymphoma. It is also approved to be used with methotrexate to treat rheumatoid arthritis. Rituximab is also being studied in the treatment of other types of cancer and other conditions.
First biosimilar approved by FDA for treatment of adult patients with non-Hodgkin’s lymphoma

First biosimilar approved by FDA for treatment of adult patients with non-Hodgkin’s lymphoma

Phase III CLL14 study evaluating Venclexta plus Gazyva to treat CLL meets its primary endpoint

Phase III CLL14 study evaluating Venclexta plus Gazyva to treat CLL meets its primary endpoint

FDA approves update to Rituxan label to include information on treatment of rare forms of vasculitis

FDA approves update to Rituxan label to include information on treatment of rare forms of vasculitis

NCCN adds COPIKTRA capsules to NCCN Guidelines for follicular lymphoma

NCCN adds COPIKTRA capsules to NCCN Guidelines for follicular lymphoma

CHMP grants positive opinion for VENCLYXTO plus rituximab for treating relapsed/refractory CLL

CHMP grants positive opinion for VENCLYXTO plus rituximab for treating relapsed/refractory CLL

Scientists discover key aspect in the development of multiple sclerosis

Scientists discover key aspect in the development of multiple sclerosis

Researchers discover key aspect in pathogenesis of multiple sclerosis

Researchers discover key aspect in pathogenesis of multiple sclerosis

Study shows B cells could play reciprocal roles in pathogenesis of systemic sclerosis

Study shows B cells could play reciprocal roles in pathogenesis of systemic sclerosis

AbbVie submits supplemental NDA to FDA for venetoclax to treat acute myeloid leukemia

AbbVie submits supplemental NDA to FDA for venetoclax to treat acute myeloid leukemia

CTI BioPharma announces Phase III results of PIXUVRI combined with rituximab in aggressive B-cell NHL patients

CTI BioPharma announces Phase III results of PIXUVRI combined with rituximab in aggressive B-cell NHL patients

Drug used to treat myelofibrosis can awaken ‘dormant’ lymphomas in the bone marrow

Drug used to treat myelofibrosis can awaken ‘dormant’ lymphomas in the bone marrow

Celgene to share new and updated data around novel hematological therapies

Celgene to share new and updated data around novel hematological therapies

Chemist begins new project to develop carbohydrate mimics to assist cancer therapies

Chemist begins new project to develop carbohydrate mimics to assist cancer therapies

New studies could offer novel treatments for vision and eye conditions

New studies could offer novel treatments for vision and eye conditions

HEV infections can be fatal and transmitted through blood products in immunosuppressed patients

HEV infections can be fatal and transmitted through blood products in immunosuppressed patients

Early and targeted treatment of dnDSA preserves allograft function

Early and targeted treatment of dnDSA preserves allograft function

Combination of chemotherapy and targeted drug improves response in younger CLL patients

Combination of chemotherapy and targeted drug improves response in younger CLL patients

Southampton researchers find new approach to reverse treatment resistance in lymphoma patients

Southampton researchers find new approach to reverse treatment resistance in lymphoma patients

Adding new antibody to chemotherapy could bolster effects of cancer treatment

Adding new antibody to chemotherapy could bolster effects of cancer treatment

ACR, AAHKS release new guideline to reduce joint infections after total hip and knee replacements

ACR, AAHKS release new guideline to reduce joint infections after total hip and knee replacements